ArticleCancers2022

Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study.

Yong-Pyo Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.